Cancer Therapy and the Human Brain: Perspectives on Neurotoxicity

Cancer is a multifaceted disease marked by the uncontrolled proliferation of cells, often affecting the central nervous system either directly or through treatment-related side effects. Cognitive impairments, such as memory loss, reduced attention span, and confusion, are frequently observed in patients undergoing therapy, significantly diminishing quality of life. While advances in chemotherapy, immunotherapy, and targeted therapies have improved survival outcomes, mounting evidence highlights their potential to induce neurotoxicity.This paper presents a narrative perspective on the cognitive and neurological consequences of modern cancer treatments. Drawing from a critical synthesis of existing literature, it examines the mechanisms underlying therapy-induced neurotoxicity, its clinical manifestations, and implications for long-term survivorship. In addition, the paper highlights gaps in current diagnostic practices and proposes the development of patient-centered assessment tools, such as surveys for self-reported cognitive decline, to complement clinical evaluations.By integrating insights from oncology, neuroscience, and patient care, this work aims to raise awareness of the neurocognitive costs of cancer therapy. Ultimately, it advocates for therapeutic strategies that not only ensure oncological control but also prioritize the preservation of brain health and quality of life in survivors.Keywords: neurotoxicity, cancer therapy, chemotherapy, immunotherapy, cognitive decline, survivorshipIntroductionCancer therapy has transformed the landscape of modern medicine, substantially improving survival rates and extending life expectancy across multiple cancer types. The advent of chemotherapy, targeted therapies, and immunotherapies has redefined what is possible in oncological care. However, these advances have also brought renewed attention to the unintended consequences of treatment, particularly those affecting the brain. Neurotoxicity, encompassing both structural and functional impairments, is increasingly recognized as a critical challenge for long-term survivorship.Cognitive dysfunction, often referred to colloquially as "chemo brain," is one of the most reported side effects, manifesting as difficulties in memory, executive function, attention, and processing speed. While initially attributed to the cytotoxic effects of chemotherapy, emerging evidence suggests that neurocognitive decline may result from a broader interplay of mechanisms, including neuroinflammation, blood–brain barrier disruption, oxidative stress, and altered neurotransmitter signaling. Importantly, such impairments may persist long after treatment ends, affecting educational attainment, employability, and psychosocial well-being.Despite its prevalence, therapy-induced neurotoxicity remains underdiagnosed and undertreated in clinical practice. Standard oncological protocols often prioritize tumor eradication over neurocognitive preservation, leading to a gap between survival outcomes and quality-of-life measures. Current diagnostic methods—ranging from neuropsychological testing to neuroimaging—offer valuable insights, yet they are limited in accessibility, scalability, and integration into routine care. Patient-reported experiences, which could provide real-time and context-specific data, remain insufficiently leveraged.This paper aims to critically examine the neurological and cognitive consequences of cancer therapies from a narrative perspective. By synthesizing existing literature and exploring pathways of neurotoxicity, it highlights the urgent need for patient-centered approaches in diagnosis and monitoring. Furthermore, it advocates for the development of integrated therapeutic strategies that balance oncological efficacy with long-term brain health, thereby reshaping survivorship to account not only for years lived but also for the quality of those years.Mechanisms of Therapy-Induced NeurotoxicityThe neurological consequences of cancer treatment are multifactorial, arising from both direct and indirect insults to the central nervous system (CNS). Although the precise pathways differ by therapeutic modality, several converging mechanisms have been implicated:Blood–Brain Barrier (BBB) Disruption: Many chemotherapeutic agents and targeted therapies alter BBB integrity, either through endothelial injury or increased permeability. This permits toxic compounds and peripheral immune cells to enter the CNS, triggering neuroinflammation and accelerating neuronal damage.Oxidative Stress and Mitochondrial Dysfunction: Treatments such as platinum-based agents (e.g., cisplatin) generate reactive oxygen species, overwhelming antioxidant defenses. Excessive oxidative stress impairs mitochondrial function, leading to apoptosis of neurons and glial cells.Neuroinflammation: Activated microglia and astrocytes release pro-inflammatory cytokines (IL-1β, TNF-α, IL-6), which disrupt synaptic plasticity and impair hippocampal neurogenesis. Persistent neuroinflammation is strongly linked to cognitive decline and mood disturbances in survivors.Altered Neurotransmitter Dynamics: Chemotherapy and immunotherapy can dysregulate dopamine, serotonin, and acetylcholine signaling, affecting circuits responsible for attention, working memory, and mood regulation.Immune-Mediated and Off-Target Effects of Immunotherapy: Checkpoint inhibitors and CAR-T cell therapies, while effective against tumors, may provoke neurotoxicity through cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), manifesting as seizures, confusion, and encephalopathy.Genetic and Epigenetic Modifications: Cancer therapies may induce DNA damage and epigenetic changes in neural progenitor cells, suppressing neurogenesis and altering long-term gene expression relevant to cognition.Together, these mechanisms reveal that therapy-induced neurotoxicity is not confined to acute toxicity but represents a complex, systemic process involving neurovascular, metabolic, and immune pathways.Clinical Manifestations of Cognitive DeclineTreatment-related neurotoxicity often manifests as a spectrum of cognitive and behavioral changes that profoundly impact daily functioning. Patients frequently report difficulties with short-term memory, attention, and executive functioning—collectively referred to as "chemo brain" or "cancer-related cognitive impairment." These deficits can present subtly, such as losing track of conversations or struggling with multitasking, but may also progress to more severe impairments that hinder occupational and social reintegration after therapy.Beyond cognition, neurotoxicity may induce mood disturbances, including anxiety, depression, and emotional lability, which further compound cognitive challenges. Sleep disruption and fatigue are common co-occurring symptoms, creating a cyclical deterioration in overall well-being. In pediatric and adolescent populations, these manifestations may impair academic performance and developmental milestones, raising long-term concerns about quality of survivorship.Importantly, the onset and severity of cognitive decline vary across treatment modalities. Chemotherapy is often associated with diffuse and persistent deficits, whereas targeted therapies and immunotherapies may cause acute but more reversible effects. Despite these distinctions, patients consistently emphasize the functional burden of neurocognitive symptoms, highlighting the urgent need for reliable diagnostic tools and patient-centered interventions.Clinical Manifestations of Cognitive DeclineTreatment-related neurotoxicity often manifests as a spectrum of cognitive and behavioral changes that profoundly impact daily functioning. Patients frequently report difficulties with short-term memory, attention, and executive functioning—collectively referred to as "chemo brain" or "cancer-related cognitive impairment." These deficits can present subtly, such as losing track of conversations or struggling with multitasking, but may also progress to more severe impairments that hinder occupational and social reintegration after therapy.Beyond cognition, neurotoxicity may induce mood disturbances, including anxiety, depression, and emotional lability, which further compound cognitive challenges. Sleep disruption and fatigue are common co-occurring symptoms, creating a cyclical deterioration in overall well-being. In pediatric and adolescent populations, these manifestations may impair academic performance and developmental milestones, raising long-term concerns about quality of survivorship.Importantly, the onset and severity of cognitive decline vary across treatment modalities. Chemotherapy is often associated with diffuse and persistent deficits, whereas targeted therapies and immunotherapies may cause acute but more reversible effects. Despite these distinctions, patients consistently emphasize the functional burden of neurocognitive symptoms, highlighting the urgent need for reliable diagnostic tools and patient-centered interventions.Table 1.